Publication | Open Access

Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers

InflammationRheumatologyDifferential ImpactAnti-inflammatoryPharmacologyGynecologyMenopausal Hormone TherapyOther Inflammatory MarkersInflammatory MarkerInflammatory Rheumatic DiseasePharmacotherapyMenopauseEndocrinologyMedicineRheumatoid ArthritisC-reactive ProteinMenopause Hormone Therapy